Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.9652W HIGH $6.16
Volume
1.10 M
Value Traded
2.73 M
Short % Float
24%
+3.5%Week
-3.97%1 Month
-13.92%3 Month
-38.85%6 Month
-50.25%5 Year
-99.47%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
303.64 M
EPS (TTM)
-1.02
P/E Ratio
-
Ent. Value
68.36 M
Total Shares
114.10 M
Float Shares
95.04 M
Insiders
16.74%
Institutions
85.86%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CATX Catalyst Timeline
Dated clinical, regulatory and corporate events for Perspective Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Perspective Therapeutics, Inc.
394Total events
12Upcoming
60Tier-1 (high impact)
2006 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Fast Track DesignationPSV-359Designation
FDA granted Fast Track Designation for PSV359 in FAP-positive solitary fibrous tumors
locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors (SFTs)source ↗
▲First Patient DosedVMT-α-NETTrial
First patient dosed in meningioma cohort of Phase 1/2a study
meningiomasource ↗
◆Oral PresentationVMT-α-NETPresentation
ASCO 2026 data analysis for VMT- -NET
SSTR2+ Neuroendocrine Tumorssource ↗
◆Oral PresentationPSV-359Presentation
Ongoing Phase 1/2a trial for PSV359
Advanced Solid Tumorssource ↗
◆Quarterly UpdateCorporate
Cash balance of ~$267.8mm expected to provide funding into mid 2026
◆Oral PresentationVMT01Presentation
ASCO 2026 poster presentation of updated Phase 1/2a data for [212Pb]VMT01
melanomasource ↗
◆Oral PresentationVMT-α-NETPresentation
ASCO 2026 poster presentation of updated Phase 1/2a data for [212Pb]VMT-α-NET
neuroendocrine tumorssource ↗
◆Oral PresentationPSV-359Presentation
ASCO 2026 publication-only presentation of Phase 1/2a data for [212Pb]PSV359
solid tumorssource ↗
▲Enrollment UpdateVMT-α-NETTrial
Proof-of-concept cohort of meningioma patients opened
meningiomasource ↗
◆Interim AnalysisVMT-α-NETTrial
Interim analysis reported at ASCO 2026 with data cut-off April 17, 2026
SSTR2-positive tumorssource ↗
▲First Patient DosedPSV-359Trial
Cohort 3 (6.0 mCi) of [212Pb]PSV359 initiated in May 2026
solid tumorssource ↗
◆Oral PresentationPSV594Presentation
First-in-human image for PSV594 presented
CCK2R-expressing cancerssource ↗
▲Interim Efficacy Datalapemelanotide zapixetarClinical Data
Interim analysis data presented at ASCO 2026
metastatic melanomasource ↗
▲Topline ReadoutVMT-α-NETClinical Data
Interim clinical data from [212Pb]VMT-α-NET study presented at 2026 ASCO Annual Meeting
SSTR2-positive tumors / neuroendocrine tumorssource ↗
▲Interim Efficacy DataVMT-α-NETClinical Data
Interim clinical data (data cut-off April 17, 2026) presented at ASCO 2026
SSTR2-positive tumors / neuroendocrine tumorssource ↗
●Oral PresentationVMT-α-NETPresentation
Interim clinical data (data cut-off April 17, 2026) presented at ASCO 2026
SSTR2-positive tumorssource ↗
▲Enrollment MilestoneVMT-α-NETTrial
Cohort 3 closed to enrollment; 20 patients treated as of April 30, 2026
neuroendocrine tumorssource ↗
▲Topline ReadoutVMT-α-NETClinical Data
Updated safety and efficacy results from dose-finding cohorts 1, 2 and 3
advanced SSTR2+ neuroendocrine tumorssource ↗
◆Enrollment MilestoneVMT-α-NETTrial
Eight DLT patients in Cohort 3 expected to have at least 32 weeks follow-up by mid-2026
neuroendocrine tumorssource ↗
◆Topline ReadoutVMT-α-NETClinical Data
First landmark analysis on all Cohort 2 patients
Neuroendocrine Tumors (NETs)source ↗
◆Timing GuidancePresentation
Multiple read-outs and milestones expected through mid-2026 and beyond
◆Oral PresentationVMT-α-NETPresentation
Updated interim data from VMT- -NET study presented at AACR 2026
neuroendocrine tumorssource ↗
▲Enrollment CompleteVMT-α-NETTrial
Enrollment completed with 64 patients treated as of data cutoff
advanced SSTR2+ neuroendocrine tumorssource ↗
▲Primary Endpoint MetVMT-α-NETClinical Data
No dose-limiting toxicities, no grade 4/5 AEs, well-tolerated
advanced SSTR2+ neuroendocrine tumorssource ↗
▲Full ResultsVMT-α-NETClinical Data
Investigator-assessed RECIST v1.1 objective responses in 10 of 23 patients (43%) in first half of Cohort 2
advanced SSTR2+ neuroendocrine tumorssource ↗
●Enrollment UpdateVMT-α-NETTrial
Treatment continues for patients enrolled in cohort 3 (6 mCi dose level)
advanced SSTR2+ neuroendocrine tumorssource ↗
●Enrollment MilestoneVMT01Trial
10 patients treated with VMT01 3.0 mCi (monotherapy or combo) as of Feb 28, 2026; cohorts closed for enrollment
melanomasource ↗
●Enrollment MilestonePSV-359Trial
8 patients treated as of Feb 28, 2026 (2 in Cohort 1, 6 in Cohort 2)
solid tumorssource ↗
▲Enrollment CompleteVMT01Trial
VMT01 3.0 mCi monotherapy and combination cohorts closed for enrollment
melanomasource ↗
▼Equity OfferingCorporate
Pricing of $175 million underwritten offering of common stock and pre-funded warrants
◆Poster PresentationVMT-α-NETPresentation
Updated interim data presented at 2026 ASCO GI Cancers Symposium
unresectable or metastatic SSTR2-positive neuroendocrine tumorssource ↗
▲Dose Finding UpdateVMT-α-NETTrial
Cohort 3 (6.0 mCi) DLT assessment completed; cleared to treat more patients
unresectable or metastatic SSTR2-positive neuroendocrine tumorssource ↗
▲Enrollment UpdateVMT-α-NETTrial
One additional patient treated in Cohort 3 after DLT clearance
unresectable or metastatic SSTR2-positive neuroendocrine tumorssource ↗
▲Topline ReadoutVMT-α-NETClinical Data
Updated interim data presented at ASCO-GI 2026
neuroendocrine tumorssource ↗
▲Oral PresentationVMT-α-NETPresentation
Updated interim data presented at ASCO-GI 2026
neuroendocrine tumorssource ↗
●Enrollment UpdateVMT01Trial
9 patients treated with VMT01 3.0 mCi as of Dec 31, 2025
melanomasource ↗
◆Topline ReadoutVMT-α-NETClinical Data
Preliminary Expansion Cohort Update for VMT-α-NET
Neuroendocrine tumorssource ↗
◆Topline ReadoutVMT01Clinical Data
Preliminary Open ICI Combo Cohort Data Update for VMT01/02 with nivolumab
Metastatic melanomasource ↗
Past FDA Catalysts and PDUFA Decisions
How CATX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | 212Pb VMT-a-NET | Phase 1/2a data readout | Phase 1/2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C44 / 100
Pipeline Score
$169M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.6x
rNPV / MCap
Top 29%
Micro Cap(rank 192 of 660)
Percentile Rank
Perspective Therapeutics, Inc. carries a moderate pipeline score (44/100), with $422M risk-adjusted pipeline value, led by VMT01 in Melanoma (Skin) (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VMT01 Small moleculeNCT05655312 | Recurrent Melanoma (Skin) | Phase 1 | RECRUITING | 300 | Dec 31, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every CATX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| [212Pb]VMT-α-NET Fast Track | unresectable or metastatic SSTR2-positive tumors | 2026-10-07 | efficacy results for half of the patients in Cohort 2 and both patients in Cohort 1Read More | Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical SymposiumRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC10% Owner | Sell | -167,149 11,273,364 held | $3.15 | 09/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CATX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 0.6 % (-33.3 %) | 26.99 M | 7.92 M |
CATX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CATX ranks across every disease it competes in
Competitive Position is a premium feature
See how CATX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCATX News
CATX▲ +10.2%on this news
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
Perspective Therapeutics has received Fast Track Designation from the FDA for PSV359, aimed at treating adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors. This designation is intended to expedite the development of therapies for serious conditions with unmet medical needs. PSV359 is currently being evaluated in a Phase 1/2a study, showing promising early imaging results.
Read more →CATX▼ -1.8%today
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
Perspective Therapeutics has announced that data from its [212Pb]VMT-α-NET program will be presented at the NANETS 2026 Multidisciplinary NET Medical Symposium. This program targets SSTR2-positive tumors using a novel radiopharmaceutical approach. The company is conducting a multi-center clinical trial and has reported interim data at the ASCO Annual Meeting. Future presentations are planned for additional data.
Read more →CATXPerspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
Perspective Therapeutics announced that data from its [212Pb]VMT01 program has been accepted for presentation at the SITC 2026 Annual Meeting. The treatment targets metastatic melanoma tumors expressing MC1R and has shown promising results in a clinical trial, with a significant percentage of patients experiencing stable disease. The company continues to advance its innovative radiopharmaceuticals for cancer treatment.
Read more →CATXPerspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
Perspective Therapeutics has entered a clinical collaboration with Merck to evaluate its targeted alpha-particle therapy, [212Pb]PSV359, in combination with Merck's Keytruda® for treating FAP-α positive solid tumors. This collaboration aims to assess the effectiveness of this combination in patients with specific cancer types, including non-small cell lung cancer and colorectal cancer. The study is part of an ongoing Phase 1/2a trial, which has completed initial enrollment.
Read more →CATXPerspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
Perspective Therapeutics announced that its updated data on the [212Pb]VMT-α-NET program has been accepted for presentation at the 38th EORTC-NCI-AACR Symposium in November 2026. The company is conducting a multi-center study on patients with unresectable or metastatic SSTR2-positive tumors. Initial efficacy data has been presented, with further results pending.
Read more →CATX▲ +6%on this news
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results
Perspective Therapeutics reported significant advancements in its clinical pipeline, including preparations for a Phase 3 study of VMT-α-NET in neuroendocrine tumors. The company has sufficient financial resources, with approximately $237 million in cash, to support its ongoing clinical milestones into late 2027. Additionally, the company announced the acceptance of a study update for oral presentation at ESMO 2026.
Read more →CATXPerspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
Perspective Therapeutics, Inc. will report its Q2 2026 financial results and provide a business update on August 10, 2026. The company is known for its pioneering work in radiopharmaceuticals targeting cancer. Their proprietary technology utilizes the isotope 212 Pb for targeted radiation therapy and is developing complementary imaging techniques. The company is also expanding its supply network for clinical drug products.
Read more →CATXPerspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
Perspective Therapeutics has received European orphan medicinal product designation for [212Pb]VMT-α-NET, aimed at treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This designation follows a positive opinion from the EMA and offers development incentives. Interim data from ongoing clinical trials suggest that [212Pb]VMT-α-NET may provide significant benefits compared to existing therapies.
Read more →CATXPerspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026
Perspective Therapeutics announced the acceptance of updated data on its [212Pb]VMT-α-NET program for oral presentation at the ESMO Congress 2026. The presentation will take place in Madrid from October 23 to 27, 2026. The company is conducting a multi-center study targeting SSTR2-positive tumors, with interim data already presented at the ASCO Annual Meeting.
Read more →CATXPerspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor
Perspective Therapeutics has appointed Dr. Paul Lyne as Chief Science Officer, succeeding co-founder Dr. Michael Schultz, who transitions to Senior Scientific Advisor. This leadership change is part of a planned transition as the company prepares for late-phase clinical development. Dr. Lyne brings over 25 years of experience in oncology research, which is expected to enhance the company's scientific strategy.
Read more →CATXPerspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
Perspective Therapeutics has initiated a Phase 1/2a study for [212Pb]VMT-α-NET, dosing the first patient in the meningioma cohort. This study aims to assess the safety and efficacy of the therapy for meningiomas, which are prevalent brain tumors. The expansion reflects the company's strategy to explore treatment for various SSTR2-expressing tumors beyond neuroendocrine tumors.
Read more →CATX▼ -7.1%on this news· ran to -18% by day 3shared move
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals Engineering the Alpha Advantage in Targeted Oncology
CATX is making strides in oncology with its next-generation radiopharmaceuticals targeting solid tumors. The ongoing Phase 1/2a trials for treatments like VMT- -NET and PSV359 demonstrate promising anti-tumor activities and a favorable safety profile. The company is optimizing its supply chain to ensure regional manufacturing and a steady production of ready-to-administer products. Their strategic focus on addressing unmet needs in the SSTR2+ neuroendocrine tumor market reinforces their commitment to innovative cancer therapies.
Read more →CATXPerspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
Perspective Therapeutics announced updates on its clinical programs to be presented at the 2026 ASCO Annual Meeting. Their findings include two confirmed responses from the [212Pb]VMT01 monotherapy cohort, and the advancement of [212Pb]PSV359 to Cohort 3 with good safety profiles. The data demonstrated positive outcomes in heavily pre-treated melanoma patients, with no reported dose limiting toxicities across programs. Further detailed results are expected by late 2026.
Read more →CATXPerspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
Perspective Therapeutics has initiated dosing for the first patients in two new cohorts of ongoing Phase 1/2a studies targeting neuroendocrine tumors and solid tumors. The studies involve innovative dosing regimens for [ 212 Pb]VMT-α-NET and [ 212 Pb]PSV359, aimed at optimizing treatment efficacy and safety. The company is advancing its clinical-stage programs and expanding its drug product supply network.
Read more →CATXPerspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
Perspective Therapeutics reported significant progress in their clinical programs and financial position for the first quarter of 2026. The company is advancing three clinical-stage oncology programs targeting various tumor types, with multiple catalysts expected later in the year. Their regional manufacturing network aims to enhance the supply chain for their radiopharmaceuticals. Despite a net loss this quarter, they maintain a substantial cash runway that supports ambitious clinical and operational plans into late 2027.
Read more →CATXAgenda Engineering the Alpha Advantage in Targeted Oncology Optimizing the Entire System Expanding the Addressable Market Unlocking New Treatment Options Across Solid Tumors: Choosing The Right Isotope Optimizing Structu
The article discusses advancements in targeted oncology with a focus on using 212Pb in theranostic approaches. It emphasizes expanding market potential through regional manufacturing and direct-to-hospital delivery of radiopharmaceuticals. Ongoing Phase 1/2a studies suggest promising results for the therapy VMT- -NET in treating neuroendocrine tumors. The article also notes potential side effects and the importance of robust supply chain configurations to meet treatment demands.
Read more →CATXPerspective Therapeutics to Provide Several Upcoming Corporate Updates
Perspective Therapeutics, Inc. announced several corporate updates scheduled for May 2026, including an analyst event and financial results. The company is focused on developing radiopharmaceutical treatments for various cancers, utilizing innovative technology for targeted therapy. Upcoming events will provide insights into their strategy and pipeline.
Read more →CATX▲ +8.3%on this news
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
Perspective Therapeutics presented updated interim data from its Phase 1/2a trial of [212Pb]VMT-α-NET at the AACR Annual Meeting 2026. The data showed a 43% objective response rate in Cohort 2, with no serious treatment-related adverse events. The treatment remains well-tolerated, and further efficacy data is expected later this year. The company is preparing for regulatory engagement and additional clinical presentations in 2026.
Read more →CATX▲ +8.3%on this news
Percent change in sum of diameters from baseline 0 1 2 3 4 5 0 8 16 24 32 40 48 56 64 72 80 88 96 Study Week Creatinine (mg/dL) Safety Analysis Set Somatosta
The article presents an update on the Phase I/IIa clinical trial for [212Pb]VMT- -NET, an alpha therapy aimed at treating SSTR2-expressing neuroendocrine tumors (NETs). As of the data cutoff on March 4, 2026, the therapy was reported to be well-tolerated with no dose-limiting toxicities. Efficacy was demonstrated through significant tumor shrinkage in some patients, although there were instances of increased blood creatinine levels and a couple of fatalities due to disease progression. Ongoing follow-up and treatment for patients in Cohorts 2 and 3 is expected to yield further results.
Read more →CATXPerspective Therapeutics to Participate in Upcoming Investor Conferences
Perspective Therapeutics, Inc. (CATX) announced its participation in two upcoming investor conferences, aiming to engage with investors and discuss its innovative radiopharmaceutical developments. The company is focusing on advanced cancer treatments and has ongoing Phase 1/2a trials for various tumor types. Their proprietary technology aims to personalize treatment and improve patient outcomes.
Read more →About Perspective Therapeutics, Inc.
Headquarters2401 ELLIOTT AVENUE, SEATTLE, WA, 98121
BIOPHARMAWATCH ELITE PLUS
Trade the next CATX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime